Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

TAT 2018 banner
Start date
05 Mar 2018
End date
07 Mar 2018
Location
Paris, France

In a constantly evolving oncology environment, ESMO continues to expand its educational offer and conference portfolio and is pleased to announce that as of 2018 ESMO is taking on the TAT Congress, which will now be held on an annual basis in Europe.

The goals and the design of phase 1 studies have changed from just safety/toxicity to now include clinical activity/response and biomarker research. This new phase 1 paradigm has already led to rapid, conditional, approval of several new cancer therapeutics showing outstanding clinical activity in early-phase studies.

TAT focuses on early-phase development and translational research. The programme covered targeted agents, immuno-oncology and combinations involving such agents. 

ESMO Press Release: Targeted Anticancer Therapies (TAT) Becomes an Annual ESMO Event

TAT 2018 Press Release: Epigenetics Therapy Shows Promise in Patients with Lymphoma

Scientific News

TAT 2018: Novel Study Explores the Genomic Landscape of Patients Achieving an Exceptional Response to Targeted Therapy

TAT 2018: Novel App Designed to Facilitate Biomarker-Driven Trials of Targeted Anti-Cancer Agents

meeting resources

Meeting Resources

Webcasts and presentations from TAT 2018 – Targeted Anticancer Therapies can be accessed by ESMO members and event attendees

Programme

Programme

Access the online programme for TAT 2018 – Targeted Anticancer Therapies!

News & Press

Press & Media

Information for media representatives including press accreditation

Contacts

Contacts

Get in touch with the organisers of TAT 2018 – Targeted Anticancer Therapies. Contact details here

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings